Tag: DESTINY-Lung01

Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC

Presented By
Dr Bob Li, Memorial Sloan Kettering Cancer Center, NY, USA
Trial
Phase 2, DESTINY-Lung01
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:36
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com